QQ客服 官方微博 反馈留言

	Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
	Liu, Jixian; Mu, Zhimin; Liu, Li; Li, Kang; Jiang, Richeng; Chen, Peng; Zhou, Qiang; Jin, Meiling; Ma, Yuxiang; Xie, Yuancai
刊名	Drug Design, Development and Therapy
	2019
卷号	13页码:1809-1817
关键词	ALK rearrangement EGFR alteration EML4-ALK Nonsmall cell lung cancer Tyrosine kinase inhibitor
ISSN号	1177-8881
DOI	10.2147/DDDT.S196189
URL标识	查看原文
WOS记录号	WOS:000469125300001
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3327927
专题	中南大学
作者单位	1.[Mu, Zhimin 2.Liu, Jixian 3.Xie, Yuancai 4.Wu, Da] Peking Univ, Dept Thorac Surg, Shenzhen Hosp, 1120 Lianhua Rd, Shenzhen 518035, Peoples R China.
推荐引用方式 GB/T 7714	Liu, Jixian,Mu, Zhimin,Liu, Li,et al. Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients[J]. Drug Design, Development and Therapy,2019,13:1809-1817.
APA	Liu, Jixian.,Mu, Zhimin.,Liu, Li.,Li, Kang.,Jiang, Richeng.,...&Wu, Da*.(2019).Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients.Drug Design, Development and Therapy,13,1809-1817.
MLA	Liu, Jixian,et al."Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients".Drug Design, Development and Therapy 13(2019):1809-1817.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。